MYGN Q3 2022 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q3 2022 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$156M-6.5% YoY

Gross Profit

$106M67.8% margin

Operating Income

-$45M-28.8% margin

Net Income

-$35M-22.4% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

-12.8%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$21M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$295M

Stockholders' Equity

$917M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$156M	$167M	-6.5%
Gross Profit	$106M	$120M	-11.3%
Operating Income	-$45M	-$80M	+43.7%
Net Income	-$35M	$25M	-242.7%

Geographic Segments

UNITED STATES

$20M66%

Non-US

$11M34%